AngioDynamics, Inc.ANGONASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

businesswire.com

AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2026 before the market open on Thursday, April 2, 2026. The Company's management will host a conference call at 8:00 am ET the same day to d.

defenseworld.net

Acuitas Investments LLC Buys 56,300 Shares of AngioDynamics, Inc. $ANGO

Acuitas Investments LLC increased its stake in AngioDynamics, Inc. (NASDAQ: ANGO) by 12.7% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 498,530 shares of the medical instruments supplier's stock after acquiring an additional 56,300 shares during the quarter. AngioDynamics makes up

defenseworld.net

AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Update

AngioDynamics, Inc. (NASDAQ: ANGO - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 2,176,310 shares, an increase of 28.1% from the February 12th total of 1,699,336 shares. Based on an average daily volume of 276,482 shares, the

zacks.com

Reasons to Add AngioDynamics Stock to Your Portfolio for Now

ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer and broad Med Tech growth supporting margins.

defenseworld.net

Contrasting Positron (OTCMKTS:POSC) and AngioDynamics (NASDAQ:ANGO)

Positron (OTCMKTS:POSC - Get Free Report) and AngioDynamics (NASDAQ: ANGO - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk. Earnings and Valuation This table compares Positron and AngioDynamics"s

defenseworld.net

AngioDynamics, Inc. (NASDAQ:ANGO) Given Average Rating of “Moderate Buy” by Analysts

AngioDynamics, Inc. (NASDAQ: ANGO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the five brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company.

businesswire.com

AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference on Monday, Mar. 9, 2026. The Company's presentation will begin at 1:40 p.m. (ET). A live we.

zacks.com

ANGO Expands NanoKnife in Europe for Multi-Organ Tumor Ablation

AngioDynamics expands NanoKnife's EU indications to liver, pancreas, kidney and prostate tumors, broadening its oncology reach and growth runway.

businesswire.com

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer. The expan.

zacks.com

Does AngioDynamics (ANGO) Have the Potential to Rally 92.15% as Wall Street Analysts Expect?

The mean of analysts' price targets for AngioDynamics (ANGO) points to a 92.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

businesswire.com

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, and The PERT Consortium®, a leading multidisciplinary organization dedicated to improving pulmonary embolism (PE) care, today announced the launch of the ALPHA-PE Research Fund, an investigator-led initiative supporting independent.

businesswire.com

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced it will convene leading cardiovascular physicians and researchers at its third Cardiovascular Scientific Forum, as the Company advances multiple cardiovascular programs following recent FDA regulatory milestones into active clinical engagemen.

zacks.com

Here's Why AngioDynamics (ANGO) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for AngioDynamics (ANGO), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

defenseworld.net

Acuitas Investments LLC Has $5.57 Million Stake in AngioDynamics, Inc. $ANGO

Acuitas Investments LLC grew its holdings in AngioDynamics, Inc. (NASDAQ: ANGO) by 12.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 498,530 shares of the medical instruments supplier's stock after purchasing an additional 56,300 shares during the quarter. AngioDynamics comprises 2.4% of

zacks.com

Reasons to Add AngioDynamics Stock to Your Portfolio for Now

ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer, and broad Med Tech growth supporting margins.

seekingalpha.com

AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

zacks.com

3 MedTech Stocks Benefiting From Favorable Product Mix Shifts

ANGO, BSX and MDT are showing earnings quality improve as higher-margin products take share, supporting margins and durable growth across MedTech.

zacks.com

Down 25.0% in 4 Weeks, Here's Why You Should You Buy the Dip in AngioDynamics (ANGO)

AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

zacks.com

ANGO Stock Dips Despite Q2 Earnings Beat, Gross Margin Improves

AngioDynamics reports flat Q2 earnings while revenue increase 8.8% and gross margin expands 170 bps on stronger Med Tech performance.

defenseworld.net

AngioDynamics Q2 Earnings Call Highlights

AngioDynamics (NASDAQ: ANGO) reported fiscal 2026 second-quarter results that management said reflected "strong" execution across the portfolio, with revenue growth and improved profitability. On the company's earnings call, President and CEO Jim Clemmer said the quarter demonstrated AngioDynamics' ability to "drive both revenue growth and profitability simultaneously," and Chief Financial Officer Steve Trowbridge detailed a higher

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance